FULL SUPPLEMENT: Mechanism Matters: IL-17 Receptor Blockade With Brodalumab and Its Role in Durable Psoriasis Clearance and Fast Onset of Action

May 2026 | Volume 25 | Issue 5 | 15470 | Copyright © May 2026


Published online April 30, 2026

Abstract
Psoriasis is a chronic immune-mediated inflammatory disease driven by dysregulated interleukin-17 (IL-17) signaling across skin and musculoskeletal tissues. While upstream IL-23 inhibition and selective IL-17 cytokine blockade have improved outcomes,
In this issue:

Clinical and Real-World Implications of IL-17 Receptor Blockade in Plaque Psoriasis and Psoriatic Arthritis With Brodalumab
Brodalumab is a fully human monoclonal antibody targeting interleukin-17 receptor A (IL-17RA), providing a mechanistically distinct approach to inhibiting IL-17–mediated inflammation in plaque psoriasis and psoriatic arthritis (approved in Japan). 

Read more

Keywords: Supplement
Close Menu